synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-20 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
=== Other countries === In Russia, methadone treatment is illegal. In 2008, the Chief Sanitary Inspector of Russia Gennadiy Onishchenko, stated that Russian health officials were not convinced of methadone's efficacy in treating heroin and/or opioid addiction. Instead of replacement therapy and gradual reduction of illicit drug use, Russian doctors encouraged immediate cessation and withdrawal. People who use drugs were generally given sedatives and non-opioid analgesics to cope with withdrawal symptoms. As of 2015, China had the largest methadone maintenance treatment program with over 250,000 people in over 650 clinics in 27 provinces.
Space food is a type of food product created and processed for consumption by astronauts during missions to outer space. Such food has specific requirements to provide a balanced diet and adequate nutrition for individuals working in space while being easy and safe to store, prepare and consume in the equipment-filled weightless environments of crewed spacecraft. Space food is commonly freeze-dried to minimize weight and ensure long shelf life. Before eating, it is rehydrated. Unmodified food, such as items of spirulina, fruit, and even a sandwich, have been brought into space. Packaging varies, including tubes, cans, and sealed plastic packages. In recent years, space food has been used by various nations engaging in space programs as a way to share and show off their cultural identity and facilitate intercultural communication. Although astronauts consume a wide variety of foods and beverages in space, the initial idea from The Man in Space Committee of the Space Science Board in 1963 was to supply astronauts with a formula diet that would provide all the needed vitamins and nutrients.
=== Economic forecasts === The economic potential of AI in the UK is claimed to be substantial. PwC has estimated that AI could increase UK GDP by 10.3% by 2030, equivalent to approximately £232 billion of additional economic value, primarily through productivity augmentation in the service sector. The UK Government's own AI Opportunities Action Plan projected that AI adoption could grow the economy by an additional £400 billion by 2030. OECD estimates suggest UK labour productivity growth from AI could reach 0.4–1.2 percentage points annually over the next decade. However, realising these gains faces what McKinsey & Company has termed a "productivity paradox". Research published in February 2026 found that while AI has demonstrated substantial productivity gains in experimental settings and for specific occupations (such as software developers, writers, and consultants), UK-wide productivity data does not yet reflect an AI-driven boost, due to low adoption rates among traditional businesses, organisational inertia, and the time required for firms to restructure workflows around new technologies.
1990 Thomas Jefferson Award from the University of Virginia Distinguished Alumni Award from the University of Minnesota Medical Alumni Association (2005) James D. Mills Award from the American College of Emergency Physicians (2008) Solomon A. Berson Award in Health Sciences from the New York University School of Medicine (2011).
== Characteristics == The small ice particle size results in greater heat transfer area than other types of ice for a given weight. It can be packed inside a container as dense as 700 kg/m3, the highest ice-packing factor among all usable industrial ice. The spherical crystals have good flow properties, making them easy to distribute through conventional pumps and piping and over product in direct contact chilling applications, allowing them to flow into crevices and provide greater surface contact and faster cooling than other traditional forms of ice (flake, block, shell, etc.). Its flow properties, high cooling capacity, and flexibility in application make a slurry ice system a substitute for conventional ice generators and refrigeration systems, and offers improvements in energy efficiency: 70%, compared to around 45% in standard systems, lower freon consumption per ton of ice, and lower operating costs.
Sources: en.wikipedia.org
=== Physical === Physical deterioration of waterlogged wood can happen immediately through the evaporation of the water. If this happens rapidly, the cells in the wood can shrink and collapse. This damage might be inevitable depending on accessibility to treatment. Additionally waterlogged wood should never be handled extensively or put on exhibit for long periods of time. Most waterlogged wood is such that decayed wood cells in the material fill with water. Depending on the wood type and how long the wood has been in water, removal of the water from the cells too rapidly (in the form of natural drying or other) could apply major stress to the cell walls and cause them to collapse. Improperly dried waterlogged irreversibly shrinks, warps, cracks and there is risk of loss to the original surface.
==== Hypoglycemic glucagon impairment ==== Glucagon secretion is normally increased upon falling glucose levels, but normal glucagon response to hypoglycemia is blunted in type 1 diabetics. Beta cell glucose sensing and subsequent suppression of administered insulin secretion is absent, leading to islet hyperinsulinemia which inhibits glucagon release. Autonomic inputs to alpha cells are far more important for glucagon stimulation in the moderate to severe ranges of hypoglycemia, yet the autonomic response is blunted in several ways. Recurrent hypoglycemia leads to metabolic adjustments in the glucose-sensing areas of the brain, shifting the threshold for counterregulatory activation of the sympathetic nervous system to lower glucose concentration. This is known as hypoglycemic unawareness. Subsequent hypoglycemia is met with impairment in the sending of counter-regulatory signals to the islets and adrenal cortex. This accounts for the lack of glucagon stimulation and epinephrine release that would normally stimulate and enhance glucose release and production from the liver, rescuing the diabetic from severe hypoglycemia, coma, and death. Numerous hypotheses have been produced in the search for a cellular mechanism of hypoglycemic unawareness. A consensus has yet to be reached. The major hypotheses are summarized in the following table:
Gonadotropin-releasing hormone (GnRH) is a releasing hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is a tropic peptide hormone synthesized and released from GnRH neurons within the hypothalamus. GnRH is inhibited by testosterone. The peptide belongs to gonadotropin-releasing hormone family. It constitutes the initial step in the activation of hypothalamic–pituitary–gonadal axis. While there are related hormones which are called Gonadotropin-releasing hormones, (GnRH2 and GnRH3), GnRH1 is the form of gonadotropin-releasing hormone that is involved in pituitary gland signaling in humans. Because of this, it is often referred to as just GnRH in this context.
=== Affinity chromatography === Affinity chromatography emerged in the 1950s as a rarely used method used to purify enzymes; it has since seen mainstream use and is the oldest among chemoproteomic approaches. Affinity chromatography is performed following one of two basic formats: ligand immobilization or target immobilization. Under the ligand immobilization format, a ligand of interest - often a drug lead - is immobilized within a chromatography column and acts as the stationary phase. A complex sample consisting of many proteins, such as a cell lysate, is passed through the column and the target of interest binds to the immobilized ligand while other sample components pass through the column unretained. Under the target immobilization format, a target of interest - often a disease-relevant protein - is immobilized within a chromatography column and acts as the stationary phase. Pooled compound libraries are then passed through the column in an application buffer, ligands are retained through binding interactions with the stationary phase, and other compounds pass through the column unretained. In both cases, retained analytes can be eluted from the column and identified using mass spectrometry. A table of elution strategies is provided below.
== Robotic platforms == Automated synthesis systems are laboratory robots that combine of software and hardware. As synthesis is a linear combination of steps, the individual steps can be modularized into hardware that accomplishes the specific step (mixing, heating or cooling, product analysis, etc.). Such hardware includes robotic arms that use dispensers and grippers to transfer materials and shakers that adjust the stirring speed and cartesian coordinate system robots that operate on a X Y Z axis and can move items and perform synthesis within designated bounds. Conditions of reactions (atmosphere, temperature, pressure) are controlled with the help of peripherals like: gas cylinders, vacuum pump, reflux system and cryostat. Modular platforms use a variety of tools in order to perform all the unit operations needed in synthesis. There are many commercial modular hardware solutions available to execute synthesis. New software programs are available that can compile an automated synthesis procedure in executable code directly from existing literature. There are also software programs that can retro-synthetically generate a procedure at the level of proficiency of a graduate student.
Sources: en.wikipedia.org
Naltrexone at a dose of 50 mg/day has been found to occupy approximately 90 to 95% of brain MORs and 20 to 35% of brain DORs. Naltrexone at a dose of 100 mg/day has been found to achieve 87% and 92% brain occupancy of the KOR in different studies. Per simulation, a lower dose of naltrexone of 25 mg/day might be expected to achieve around 60% brain occupancy of the KOR but still close to 90% occupancy of the MOR. In a study of the duration of MOR blockade with naltrexone, the drug with a single 50 mg dose showed 91% blockade of brain [11C]carfentanil (a selective MOR ligand) binding at 48 hours (2 days), 80% blockade at 72 hours (3 days), 46% blockade at 120 hours (5 days), and 30% blockade at 168 hours (7 days). The half-time of brain MOR blockade by naltrexone in this study was 72 to 108 hours (3.0 to 4.5 days). Based on these findings, doses of naltrexone of even less than 50 mg/day would be expected to achieve virtually complete brain MOR occupancy. Blockade of brain MORs with naltrexone is much longer-lasting than with other opioid antagonists like naloxone (half-time of ~1.7 hours intranasally) or nalmefene (half-time of ~29 hours). The half-life of occupancy of the brain MOR and duration of clinical effect of naltrexone are much longer than suggested by its plasma elimination half-life. A single 50 mg oral dose of naltrexone has been found to block brain MORs and opioid effects for at least 48 to 72 hours.
These reviews suggest that lisdexamfetamine is persistently effective at treating BED and is associated with significant reductions in the number of binge eating days and binge eating episodes per week. Furthermore, a meta-analytic systematic review highlighted an open-label, 12-month extension safety and tolerability study that reported lisdexamfetamine remained effective at reducing the number of binge eating days for the duration of the study. In addition, both a review and a meta-analytic systematic review found lisdexamfetamine to be superior to placebo in several secondary outcome measures, including persistent binge eating cessation, reduction of obsessive-compulsive related binge eating symptoms, reduction of body-weight, and reduction of triglycerides. Lisdexamfetamine, like all pharmaceutical amphetamines, has direct appetite suppressant effects that may be therapeutically useful in both BED and its comorbidities. Based on reviews of neuroimaging studies involving BED-diagnosed participants, therapeutic neuroplasticity in dopaminergic and noradrenergic pathways from long-term use of lisdexamfetamine may be implicated in lasting improvements in the regulation of eating behaviors that are observed.
Such an increase in sulfate aerosol emissions had a variety of effects. At the time, the most visible one was acid rain, caused by precipitation from clouds carrying high concentrations of sulfate aerosols in the troposphere. At its peak, acid rain has eliminated brook trout and some other fish species and insect life from lakes and streams in geographically sensitive areas, such as Adirondack Mountains in the United States. Acid rain worsens soil function as some of its microbiota is lost and heavy metals like aluminium are mobilized (spread more easily) while essential nutrients and minerals such as magnesium can leach away because of the same. Ultimately, plants unable to tolerate lowered pH are killed, with montane forests being some of the worst-affected ecosystems due to their regular exposure to sulfate-carrying fog at high altitudes. While acid rain was too dilute to affect human health directly, breathing smog or even any air with elevated sulfate concentrations is known to contribute to heart and lung conditions, including asthma and bronchitis. Further, this form of pollution is linked to preterm birth and low birth weight, with a study of 74,671 pregnant women in Beijing finding that every additional 100 μg/m3 of SO2 in the air reduced infants' weight by 7.3 g, making it and other forms of air pollution the largest attributable risk factor for low birth weight ever observed.
=== Franchisee Recognition Award === Domino's recognizes excellence by franchisees through its annual Golden Franny Awards, which the company cites as "the most prestigious honor bestowed upon a Domino’s franchisee." The award recognizes franchise owners who serve as brand ambassadors, give back to their communities in meaningful ways and lend a helping hand to their fellow franchisees. Gold Franny recipients are an elite group within Domino's, as about 750 franchise owners across the United States have received the award over the years as of 2025. Selection for the Golden Franny Award is based on several factors, including operational audit scores, community involvement, store safety and security, and team member morale.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.